glioma tissues; adjacent non-tumor tissues; cancerous and adjacent noncancerous tissues; tumor tissues
U251; A172; TJ861; TJ905; LN18; HEB
cell line-derived xenograft
PI3K/AKT (promotes); proliferation (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); apoptosis (inhibits); ceRNA regulation (other)
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Western Blot; Transwell Assay; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis
Higher circFAM53B levels were associated with poorer survival of glioma patients and the circFAM53B/miR-532-3p/c-MET/PI3K/AKT axis is proposed as a potential treatment target for glioma.
circFAM53B is up-regulated in glioma tissues and cell lines, and higher expression predicts poorer patient survival. Functionally, it promotes glioma proliferation, invasion, EMT and in vivo tumor growth while suppressing apoptosis. Mechanistically, circFAM53B sponges miR-532-3p to activate the MET/c-MET-mediated PI3K/AKT pathway.
0.7789
CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p.
combined biological and clinical study